OBJECTIVES: Stereotactic body radiation therapy (SBRT) is an emerging treatment option for @entity96 unsuitable for ablation or surgery. We report our experience with SBRT in the treatment of @entity96 . MATERIALS AND METHODS: @entity1 with @entity96 were identified in our local SBRT database. @entity1 were included irrespective of prior liver-directed therapies. The primary endpoint of our review was in-field local control (LC). Secondary endpoints were progression-free survival (PFS), overall survival (OS), and @entity137 . RESULTS: From 2009 to 2015, a total of 71 @entity409 in 68 @entity1 were treated with SBRT (three @entity1 had two @entity409 treated). The median age was 71 years (27-89 years). @entity157 ( @entity157 ) was the diagnosis in 23 @entity1 (34%), with the grade of @entity1 -Pugh A (52%), B (39%), or C (nine percent) @entity82 . Six @entity1 (nine percent) had @entity1419 ( @entity1419 ). The remaining 39 @entity1 (57%) had metastatic @entity409 . @entity14 was the most common @entity5 type (81%). The median size for @entity157 , @entity1419 , and metastatic lesions was 5 cm (2-9 cm), 3.6 cm (2-4.9 cm), and 4 cm (1-8 cm), respectively. The median prescribed dose was 45 Gy (16-50 Gy). Median follow-up was 11.5 months (1-45 months). Actuarial one-year in-field LC for @entity157 and metastatic lesions was 85% and 64% respectively (p= 0.66). At one year, the actuarial rate of new @entity409 was 40% and 26%, respectively, (p=0.58) for @entity157 and @entity3 . Only six @entity1 with @entity1419 were treated with SBRT in this study - in these @entity1 , one-year LC was 78% with new @entity409 in 53%. The SBRT treatments were well tolerated. The side effects included common criteria for adverse events (CTCAE) v4 grade 1 acute @entity344 in three @entity1 , grade 3 @entity390 in one @entity1 , and grade 3 acute @entity1909 in another @entity1 . Two @entity1 had grade 5 @entity137 . @entity1207 was observed in one @entity1 two months post-SBRT treatment, and another @entity1 was suspected to have had @entity99 ( @entity99 ) two months after SBRT. No late @entity137 was seen. CONCLUSION: SBRT is a well-tolerated and effective alternative treatment option for selected @entity1 with primary and metastatic @entity96 .

Stereotactic Body Radiotherapy for Inoperable XXXX : Results of a Single Institutional Experience.

@entity1 :: ('9606', 'Species') :: ['Child', 'patient', 'Patients', 'patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity82 :: ('MESH:D005355', 'Disease') :: ['cirrhosis'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity96 :: ('MESH:D008113', 'Disease') :: ['primary or secondary liver cancer', 'liver tumors'] @entity5 :: ('MESH:D009369', 'Disease') :: ['primary tumor'] @entity409 :: ('MESH:D008107', 'Disease') :: ['liver lesions'] @entity344 :: ('MESH:D005767', 'Disease') :: ['gastrointestinal toxicity'] @entity1207 :: ('MESH:D017564', 'Disease') :: ['Radiation pneumonitis'] @entity1419 :: ('MESH:C535533', 'Disease') :: ['intrahepatic cholangiocarcinoma', 'IHC'] @entity14 :: ('MESH:D015179', 'Disease') :: ['Colorectal adenocarcinoma'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases'] @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'Hepatocellular carcinoma'] @entity99 :: ('MESH:D056486', 'Disease') :: ['radio-induced liver disease', 'RILD'] @entity1909 :: ('MESH:D003872', 'Disease') :: ['dermatitis']
@entity96 :: (MESH:D008113,Disease) :: ['Liver Tumors']
